InsiderTrades.com logo
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing   |   Ad
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
I put all the details together for you here — but please hurry. 
Robert Wong net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Robert Wong Biography and Net Worth

CAO of Cytokinetics

Robert has been our Chief Accounting Officer since May 2019.

Prior to joining Cytokinetics, Robert was at Genentech for over 23 years with roles of increasing responsibility in accounting, reporting, and internal controls, most recently as Interim Controller and Chief Accounting Officer. He has extensive experience in accounting for mergers, acquisitions and business development collaborations, reporting under US and International accounting standards, and complying with internal control regulations. Prior to Genentech, Robert was an Audit Manager at Ernst & Young LLP for over seven years.

Robert received his B.S. in Business Administration, Accounting & Finance from the University of California, Berkeley and is a certified public accountant.

A native San Franciscan, Robert enjoys his spare time working on a house or car repair project and spending time with his wife and three kids during their school and dance activities.

What is Robert Wong's net worth?

The estimated net worth of Robert Wong is at least $813,832.11 as of June 3rd, 2024. Mr. Wong owns 16,653 shares of Cytokinetics stock worth more than $813,832 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Wong may own. Additionally, Mr. Wong receives an annual salary of $495,720.00 as CAO at Cytokinetics. Learn More about Robert Wong's net worth.

How old is Robert Wong?

Mr. Wong is currently 56 years old. There are 5 older executives and no younger executives at Cytokinetics. The oldest executive at Cytokinetics is Dr. James A. Spudich Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 82 years old. Learn More on Robert Wong's age.

What is Robert Wong's salary?

As the CAO of Cytokinetics, Incorporated, Mr. Wong earns $495,720.00 per year. There are 3 executives that earn more than Mr. Wong. The highest earning executive at Cytokinetics is Mr. Robert I. Blum, President and Chief Executive Officer, who commands a salary of $1,330,000.00 per year. Learn More on Robert Wong's salary.

How do I contact Robert Wong?

The corporate mailing address for Mr. Wong and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Robert Wong's contact information.

Has Robert Wong been buying or selling shares of Cytokinetics?

Robert Wong has not been actively trading shares of Cytokinetics during the past quarter. Most recently, Robert Wong sold 13,011 shares of the business's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $48.88, for a transaction totalling $635,977.68. Following the completion of the sale, the chief accounting officer now directly owns 16,653 shares of the company's stock, valued at $813,998.64. Learn More on Robert Wong's trading history.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 48 times. They sold a total of 454,133 shares worth more than $28,606,030.33. The most recent insider tranaction occured on December, 16th when Director Wendall Wierenga sold 742 shares worth more than $36,068.62. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.

Information on this page was last updated on 12/16/2024.

Robert Wong Insider Trading History at Cytokinetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2024Sell13,011$48.88$635,977.6816,653View SEC Filing Icon  
2/21/2023Sell2,234$45.21$100,999.1424,789View SEC Filing Icon  
2/3/2023Sell3,004$45.00$135,180.0027,533View SEC Filing Icon  
11/14/2022Sell2,100$40.68$85,428.0030,537View SEC Filing Icon  
See Full Table

Robert Wong Buying and Selling Activity at Cytokinetics

This chart shows Robert Wong's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $48.87
Low: $46.85
High: $50.32

50 Day Range

MA: $52.09
Low: $46.36
High: $58.62

2 Week Range

Now: $48.87
Low: $36.24
High: $110.25

Volume

3,805,196 shs

Average Volume

1,988,956 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8
AI breakthrough about to upend industry
From Porter & Company   |   Ad
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
I urge you to watch it now.